8-K   

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 27, 2016

Illumina, Inc.

(Exact name of registrant as specified in its charter)

001-35406

(Commission File Number)

Delaware 33-0804655

(State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.)

5200 Illumina Way, San Diego, CA 92122

(Address of principal executive offices) (Zip code)

(858) 202-4500

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02, Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Effective as of January 27, 2016, the Board of Directors (the "Board") of Illumina, Inc. (the "Company") increased the size of the Board from 10 to 11 members and elected Frances Arnold, Ph.D., to serve on the Board. Dr. Arnold has been assigned to serve in the class of directors standing for election at the Company’s 2016 annual meeting of stockholders, which currently includes Francis deSouza and David Walt, and, consistent with the Company’s Corporate Governance Guidelines, Dr. Arnold will stand for election by the Company’s stockholders at the Company’s 2016 annual meeting of stockholders to serve for a three-year term commencing with such meeting. There is no arrangement or understanding between Dr. Arnold and any other person pursuant to which she was selected as a director. In addition, Dr. Arnold is not a party to any transaction with the Company reportable under Item 404(a) of Regulation S-K under the Securities Act of 1933. Dr. Arnold will participate in the non-employee director compensation programs described under "Director Compensation" in the Company's proxy statement filed on April 8, 2015. A copy of the Company's press release announcing Dr. Arnold’s appointment is filed as Exhibit 99.1 to this Form 8-K. 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press release dated January 28, 2016 announcing the appointment of Dr. Frances Arnold to its Board of Directors.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

[DATA_TABLE_REMOVED]